On January 24, 2023, the U.S. Food and Drug Administration (FDA) issued marketing denial orders (MDOs) for Vuse menthol products. While this is a huge step backward for responsible adult vapers that simply want a nicotine e-cig that meets their needs, the company must now resubmit applications or submit new applications to address any deficiencies of the products outlined within the MDOs. If you want to learn more about why Vuse menthol products were not approved for sale and marketing in the U.S. continue reading for everything we know so far.
How did the FDA make its decision?
When reviewing premarket tobacco product applications (PMTAs), the agency evaluates the product’s components, including ingredients, additives, constituents, design, harmful and potentially harmful constituents and health risks, as well as how the product is manufactured, packaged, and labeled. After reviewing the sufficient evidence within the manufacturer’s application, the FDA determines whether permitting the marketing of said products would be appropriate for the protection of public health.
Why did the FDA not approve Vuse menthol products?
What does this mean for vapers who use Vuse menthol?
Many responsible adult vapers rely on Vuse menthol products to keep themselves smoke-free. They also utilize these e-cig products to lower their nicotine intake when they quit combustible cigarettes. Not only does this denial for sales and marketing in the U.S. hurt those who need these products the most, but it also limits access and drives users back to their past smoking routines.
The R.J. Reynolds Vapor Company will be updating its application to provide further evidence that Vuse menthol products are needed are approved smoking cessation aids, and that the potential benefit to adult smokers outweigh the risks of youth initiation and use. However, in the meantime, we recommend stocking up on Vuse menthol products to ensure that you have what you need to continue your tobaccoless journey.
Do you prefer to vape tobacco or menthol? Drop a comment below to share with our readers.